<DOC>
	<DOCNO>NCT02328027</DOCNO>
	<brief_summary>The objective study : Primary objective : - To determine safety tolerability medical image 99mTc-rhAnnexin V-128 Secondary objective : - To determine biodistribution , pharmacokinetics radiation dosimetry 99mTc-rhAnnexin V-128 - To demonstrate time-dependant distribution localization 99mTc-rhAnnexin V-128 RA AS patient - To determine ability early image 99mTc-rhAnnexin V-128 evaluate presence lesion short term treatment either RA AS patient . Study hypothesis : 99mTc-rhAnnexin V-128 could use adjunct diagnosis early stage rheumatoid arthritis ankylose spondylitis assessment response treatment disease .</brief_summary>
	<brief_title>99mTc-rhAnnexin V-128 Phase I/IIa Study Patients With Rheumatoid Arthritis ( RA ) Ankylosing Spondylitis ( AS )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis , Ankylosing</mesh_term>
	<criteria>Patients diagnose RA base ACR/EULAR 2010 criterion ( score &gt; =6 ) , Patients diagnose AS base ASAS criterion . Patients RA must serology assessment perform documented time enrollment . Patient RA active disease ( DAS &gt; 2,6 ) introduction BiDMARD indicate . RA patient must treat DMARD ( methotrexate , leflunomide sulfasalazine ) combination treatment least 3 month . Treatment pursue study . RA patient must previously treat BiDMARD initiation new BiDMARD treatment . The nonresponse previous BiDMARD treatment must document . Patients AS insufficiently control disease NSAID indication BiDMARD . These patient must NSAID least 3 month NSAID least 1 month prior enrollment . ≥ 18 year old Karnofsky ≥ 80 % Negative Pregnancy test woman childbearing potential For woman childbearing potential , use two reliable mean contraception ( e.g. , hormonal contraceptive , patch , vaginal ring , intrauterine device , associate barrier method contraception use condom ) , throughout participation study Absence ECG anomaly write ICF sign Pregnancy lactation Liver impairment ( ALT , AST Bilirubin &gt; 2 ULN ) screen visit baseline Kidney impairment ( serum creatinine &gt; 1.5 mg/dL ) History congestive heart failure ( NYHA III &amp; IV ) History malignant disease within 5 year History disease relevant physical psychiatric condition abnormal physical finding may interfere study objective investigator judgment Known hypersensitivity investigational drug component Participation another clinical trial within 4 week study inclusion except patient participate currently participate interventional study without study drug administration .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>